within Pharmacolibrary.Drugs.ATC.J;

model J05AR26
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 6.29 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,
    adminCount     = 1,
    Vd             = 0.00237,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019166666666666665,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Darunavir is a protease inhibitor used in combination with ritonavir, a pharmacokinetic enhancer, for the treatment of Human Immunodeficiency Virus (HIV) infection. The ritonavir component boosts darunavir levels by inhibiting CYP3A-mediated metabolism. This fixed-dose combination is approved as antiretroviral therapy for HIV-1 infection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects; darunavir/ritonavir 800 mg/100 mg administered orally once daily.</p><h4>References</h4><ol><li><p>Kakuda, TN, et al., &amp; Hoetelmans, RM (2014). Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food. <i>Clinical pharmacology in drug development</i> 3(5) 346–352. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.88&quot;>10.1002/cpdd.88</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27129006/&quot;>https://pubmed.ncbi.nlm.nih.gov/27129006</a></p></li><li><p>Yu, CY, et al., &amp; Morgan, RE (2014). Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. <i>Clinical drug investigation</i> 34(7) 475–482. DOI:<a href=&quot;https://doi.org/10.1007/s40261-014-0198-x&quot;>10.1007/s40261-014-0198-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24825411/&quot;>https://pubmed.ncbi.nlm.nih.gov/24825411</a></p></li><li><p>Dickinson, L, et al., &amp; Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>The Journal of antimicrobial chemotherapy</i> 75(3) 628–639. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkz479&quot;>10.1093/jac/dkz479</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31754703/&quot;>https://pubmed.ncbi.nlm.nih.gov/31754703</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AR26;
